Molecular indicators of prognosis in mantle cell lymphoma in the era of R-hyper-CVAD: still an open issue

Leuk Lymphoma. 2007 Aug;48(8):1461-2. doi: 10.1080/10428190701474399.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B
  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism
  • ATP Binding Cassette Transporter, Subfamily G, Member 2
  • ATP-Binding Cassette Transporters / metabolism
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, Neoplasm / metabolism
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biomarkers, Tumor / metabolism*
  • Cyclophosphamide / therapeutic use
  • DNA Topoisomerases, Type II / metabolism
  • DNA-Binding Proteins / metabolism
  • Dexamethasone / therapeutic use
  • Doxorubicin / therapeutic use
  • Drug Resistance, Neoplasm
  • Glutathione S-Transferase pi / metabolism
  • Humans
  • Lymphoma, Mantle-Cell / drug therapy*
  • Lymphoma, Mantle-Cell / metabolism
  • Neoplasm Proteins / metabolism
  • Prognosis
  • Rituximab
  • Vincristine / therapeutic use

Substances

  • ABCB1 protein, human
  • ABCG2 protein, human
  • ATP Binding Cassette Transporter, Subfamily B
  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • ATP Binding Cassette Transporter, Subfamily G, Member 2
  • ATP-Binding Cassette Transporters
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, Neoplasm
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • DNA-Binding Proteins
  • Neoplasm Proteins
  • Rituximab
  • Vincristine
  • Dexamethasone
  • Doxorubicin
  • Cyclophosphamide
  • Glutathione S-Transferase pi
  • DNA Topoisomerases, Type II

Supplementary concepts

  • CVAD protocol